Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 365 clinical trials
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.  

measurable disease
solid tumors
administration intravenous
solid tumor
  • 25 Aug, 2021
  • 57 locations
  • 26 Jan, 2021
  • 11 locations
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-295S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor. It will be

  • 11 Sep, 2021
  • 1 location
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

To evaluate the safety and tolerability of LXI-15029 in Chinese patients with advanced malignant solid tumors in monotherapy period, including confirmation of the maximum tolerated dose

tumor cells
measurable disease
locally advanced breast cancer
epidermal growth factor receptor
  • 26 Jan, 2021
  • 1 location
A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR). This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin.

  • 06 Sep, 2021
  • 40 locations
Safety Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC) in Patients With Advanced Malignant Solid Tumors

advanced malignant solid tumors and to explore the pharmacokinetic characteristics of T601, 5-FC, 5-FU, FBAL, which includes PhI study of dose-escalation study and Ph IIa study of extending study.

  • 27 Jan, 2021
  • 2 locations
Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors

The goal of this clinical trial is to study the safety, efficacy, and pharmacokinetics of mRNA-engineered anti-Mesothelin (MESO) Chimeric Antigen Receptor T-Cell (CAR-T cells) therapy in patients with mesothelin expression-positive, advanced solid tumors that have failed at least first-line or second-line therapy.

  • 19 Sep, 2021
  • 1 location
Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.

  • 25 Jan, 2021
Safety Tolerability and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

This is a multi-center, open-label, dose-escalation, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics of CAL056 mesylate in cancer patients with resistant or refractory solid tumors.

  • 19 Jun, 2021
  • 3 locations
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter

The goal of this clinical research study is to learn if giving autologous lymphocyte infusions to patients who are receiving chemotherapy and radiation for non-small cell lung cancer or esophageal cancer is safe and effective.

  • 29 Jan, 2021
  • 1 location